No interstitial lung disease or grade ≥3 adverse events occurred in these four patients.<h4>Conclusion</h4>The potential of T-DXd in patients with metastatic NSCLC harboring <i>HER2</i> non-exon 19/20 mutations is considerable, which deserves to be validated in large-sample studies. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.